Quality assurance in Her-2 testing - Redefining the gold standard

Clinical Chemistry

Volumn 55, Issue 7, 2009, Pages 1265-1267

  Thomas, Jeremy St J ^a,b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b Breakthrough Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; QUANTUM DOT; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CELL LINE; CORRELATION ANALYSIS; EDITORIAL; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PROGNOSIS; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARD;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; GENETIC SCREENING; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 67650085788     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.126219     Document Type: Editorial

References (13)

1. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. Her2 and response to Paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506.
2. Xiao Y, Gao X, Maragh S, Telford WG, Tona A. Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer. Clin Chem 2009;55:1307-15.
3. Ibrahim M, Miller K. HER-2 testing: the value of national audit, external quality assessment (UK NEQAS) and laboratory accreditation (CPA-UK-Ltd). Histopathology 2008;53(s1):41. http://www3.interscience.wiley.com.ezproxy. webfeat.lib.ed.ac.uk/journal/121419845/issue (Accessed May 2009).
4. Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
5. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
6. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23.
7. Hammond ME, Barker P, Taube S, Gutman S. Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored consensus workshop. Appl Immunohistochem Mol Morphol 2003;11:103-6.
8. Xiao Y, Barker PE. Semiconductor nanocrystal probes for human metaphase chromosomes. Nucleic Acids Res 2004;32:e28.
9. Medintz IL, Mattoussi H, Clapp AR. Potential clinical applications of quantum dots. Int J Nanomedicine 2008;3:151-67.
10. Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol 2004;122:51-60.
11. Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, et al. External quality assurance of HER2 FISH and ISH testing: three years of the UK National External Quality Assurance Scheme. Am J Clin Pathol 2009;131:106-11.
12. Faratian D, Graham AG, Rae F, Thomas J. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 2009;54:428-32.
13. Byers RJ, Di Vizio D, O'Connell F, Tholouli E, Levenson RM, Gossage K, et al. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn 2007;9:20-9.